The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
Abstract
OBJECTIVE: To define the rate, timing, and clinical risk factors for the development of autoimmune disease (AID) after alemtuzumab treatment for multiple sclerosis (MS). METHODS: We analyzed prospective clinical and serologic data from 248 patients with MS treated with alemtuzumab, with median follow-up of 34.3 months (range 6.7-107.3). RESULTS: Novel AID developed in 22.2%. Thyroid AID was most frequent (15.7%). A range of hematologic, renal, and dermatologic AID were also observed as was asymptomatic development of novel autoantibodies. AID was seen from 2 weeks after initial treatment and was most frequent 12-18 months after first treatment. No new cases of AID were identified 60 months or more after initial treatment and risk of AID was independent of total alemtuzumab dose or interval of dosage. While established risk factors for AID including sex and age had no impact on AID frequency, both family history (odds ratio = 7.31, 95% confidence interval 3.02-17.68) of AID and a personal smoking history (odds ratio = 3.05, 95% confidence interval 1.50-6.19) were predictive of AID expression. CONCLUSIONS: Cumulative risk for AID in MS following alemtuzumab is 22.2%, most frequent between 12 and 18 months following first dose and evident for up to 5 years. Individual risk is modified by smoking and family history, which should be incorporated within the counseling process prior to treatment. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that the risk of AID after alemtuzumab treatment for MS is time-limited and modified by external factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while others did not [12, 77].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [77]
In the citing paper
“In the studies that have, most patients responded to antithyroid drugs (ATDs) [1214, 50, 77], at least initially.”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [77]
In the citing paper
“In contrast, requirements for RAI or surgery were lower than expected in conventional GD in some reports; 14% [14], 27% [77].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [77]
Citations
Cites
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
The CAMMS Trial Investigators (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,021
Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.
King, C., Ilic, A., Koelsch, K., & Sarvetnick, N. (2004) · Cell · doi:10.1016/s0092-8674(04)00335-6 · Cited by 747
The window of therapeutic opportunity in multiple sclerosis
Coles, A. J., Cox, A., Page, E. L., Jones, J., Trip, S. A., Deans, J., Seaman, S. R., Miller, D. H., Hale, G., Waldmann, H., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02429-0 · Cited by 453
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis
Hedström, A. K., Bäärnhielm, M., Olsson, T. P., & Alfredsson, L. S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59c40 · Cited by 323
Jones, J., Phuah, C., Cox, A. L., Thompson, S. A. J., Ban, M., Shawcross, J., Walton, A., Sawcer, S. J., Compston, A., & Coles, A. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37878 · Cited by 296
Prevalence of immune thrombocytopenia: analyses of administrative data
Segal, J. B., & Powe, N. R. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02147.x · Cited by 269
Autoimmune disease in first-degree relatives of patients with multiple sclerosis
Broadley, S., Deans, J., Sawcer, S. J., Clayton, D. G., & Compston, D. A. S. (2000) · Brain · doi:10.1093/brain/123.6.1102 · Cited by 210
Nakamura, Y., Miyata, M., Ohba, T., Ando, T., Hatsushika, K., Suenaga, F., Shimokawa, N., Ohnuma, Y., Katoh, R., Ogawa, H., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.022 · Cited by 158
Smoking as a Risk Factor for Graves' Disease, Toxic Nodular Goiter, and Autoimmune Hypothyroidism
Vestergaard, P., Rejnmark, L., Weeke, J., Hoeck, H. C., NIELSEN, H. K., Rungby, J., Laurberg, P., & Mosekilde, L. (2002) · Thyroid · doi:10.1089/105072502753451995 · Cited by 128
Research works printed but not linked: 3
- Marsh EA, Hirst CL, Llewelyn JG, et al.. Alemtuzumab in the treatment of chronic immune demyelinating polyneuropathy. J Neurol Epub 2010 Jan 6.
- Munteis E, Segura N, Martinez J, Cuadrado E, Galvez A, Roquer J. Idiopathic thrombocytopenic purpura in patients with multiple sclerosis. Mult Scler 2006;12:S210. Abstract.
- Kirby S, Brown MG, Murray TJ, et al.. Prevalence of other autoimmune diseases in patients with multiple sclerosis. Mult Scler 2005;11:S29. Abstract.
Cited by
Sorted by citations
Items 201–215 of 215
Mécanismes d’actions des biothérapies dans la SEP
Bernard‐Valnet, R., & Brassat, D. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-71420-7.00006-9
Klotz, L., Berthele, A., Brück, W., Chan, A., Flachenecker, P., Gold, R., Haghikia, A., Hellwig, K., Hemmer, B., Hohlfeld, R., et al. (2016) · doi:10.7892/boris.87818
Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
Nosher, S., Fuad, S., Mishra, N., Alrashid, Z. A., Rathod, B., Mohan, D., Basavanagowda, D. M., Kaur, A., & Heindl, S. E. (2021) · Cureus · doi:10.7759/cureus.13246
Causes and Laboratory Investigations of Thyrotoxicosis
Latrofa, F., & Vitti, P. (2022) · doi:10.1093/med/9780198870197.003.0058
(2019) · Reactions Weekly · doi:10.1007/s40278-019-69726-z
Verbout, N. G., Su, W., Pham, P. T., Jordan, K. R., Kohs, T. C. L., Tucker, E. I., McCarty, O. J. T., & Sherman, L. S. (2023) · Research Square · doi:10.21203/rs.3.rs-2802415/v1
Alemtuzumab y síndrome poliglandular autoinmune con diabetes mellitus tipo 1
Estévez, D. A. G., Pinal-Osorio, I., & Pato, A. P. (2024) · Neurología · doi:10.1016/j.nrl.2023.07.001
Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus
Estévez, D. A. G., Pinal-Osorio, I., & Pato, A. P. (2024) · Neurología (English Edition) · doi:10.1016/j.nrleng.2024.02.006
Sahraian, M. A., Emami, S., Ataei, S., & Ghalandari, N. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03386-z
“However, its complications such as secondary autoimmune disease, necessitate careful monitoring and management (Cossburn et al. 2011).”
Karussis, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00343-4
Kira, J., & Isobe, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_15-1
Trinchillo, A., Carotenuto, A., Spiezia, A. L., Caliendo, D., Severino, A., Monaco, C. D., Iacovazzo, C., Servillo, G., Morra, V. B., & Lanzillo, R. (2024) · Sclerosis · doi:10.3390/sclerosis2040020
Clinical commentary to “Alemtuzumab: balancing risks”
Robertson, N. P. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251365794
Höpner, L., Marschall, E., Schindler, P., Frauendorf, V., Böhmig, M., Rakers, F., Karimi, D., Faber, C., Ruprecht, K., & Otto, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1753387
“…a causal contribution of ocrelizumab in the development of these disorders (8 – 11 , Immune-mediated adverse reactions such as psoriasis, Graves ’ disease and rheumatoid arthritis have also been reported with other DMTs used in MS, including interferons, natalizumab and alemtuzumab (16 – 20).”
Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion
Hunt, D. P. J. (2026) · Brain · doi:10.1093/brain/awag308
Metadata
- Authors
- Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., Pickersgill, T., Ben-Shlomo, Y., Coles, A., & Robertson, N. P.
- Affiliations
- University of Cambridge (GB)
- From the Department of Psychological Medicine and Neurology (M.C., G.I., K.B., C.H., T.P., N.P.R.), Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK; Department of Neurology (A.A.P., J.Z.), Penninsula Medical School, Tamar Science Park, Derriford, Plymouth; Neurology Unit (J.J., A.C.), Department of Clinical Neurosciences, Cambridge University, Addenbrooke's Hospital, Cambridge; Department of Neurology (R.A., M.B.), The Walton Centre NHS Foundation Trust, Fazakerley,...
- Venue
- Neurology
- Published
- 2011-08-09
- Volume
- 77
- Issue
- 6
- Pages
- 573-579
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2110867277
- Cited by
- 216
- References
- 23
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 11 · 2022: 11 · 2021: 7 · 2020: 10 · 2019: 18 · 2018: 17 · 2017: 16 · 2016: 25 · 2015: 14 · 2014: 19 · 2013: 22 · 2012: 23
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- National Institute for Health and Care Research (CL-2008-14-004)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- alemtuzumab, multiple sclerosis, autoimmune disease, thyroid autoimmunity, smoking, family history (medicine), risk factors, treatment safety
- MeSH terms
- Alemtuzumab, Adolescent, Adult, Aged, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Neoplasm, Antineoplastic Agents, Autoantibodies, Autoimmune Diseases, Counseling, Female, Follow-Up Studies, Humans, Male, Methylprednisolone, Middle Aged, Multiple Sclerosis, Prospective Studies, Risk Factors, Smoking, Thyroid Diseases, Cohort Studies, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
